amantadine

The Double-edged Sword of Fatigue Medications

ā€œI close my eyes/ Only for a moment then the momentā€™s gone/ All my dreams pass before my eyes, a curiosity.ā€ ā€” Kansas, “Dust in the Wind”Ā  The dark cloud of fatigue first swept through my mind toward the end of 2018. I was no stranger to physical fatigue,…

ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial

  An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative…

There Is No Magic Pill for MS Fatigue

I’ve been tired all day, which is nothing new, as fatigue and multiple sclerosis go hand in hand. It’s been one of my primary symptoms since I was diagnosed in 1980. To counter it, I’ve taken Provigil (modafinil) for many years. Initially, taking 100 mg in the morning helped…

1st Patient Enrolls in Phase 3 Trial of ADS-5102 as Way of Improving Walking Ability, Adamas Announces

A Phase 3 trial testing an oral once-a-day therapy ā€” ADS-5102 (amantadine) extended release capsules ā€” inĀ multiple sclerosis (MS) patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced. The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites…

Modafinil or Amantadine: Who Decides?

Fatigue. That No. 1 symptom that a large majority of people with multiple sclerosis are affected by. MS fatigue. It can be crushing, numbing, and stop the hardiest person in their tracks. I know MS fatigue all too well because it affects me all the time. Combating MS…

#ACTRIMS2017 – Phase 2 Trial Data Shows Better Walking Speeds in MS Patients Using ADS-5102

Results from aĀ Phase 2 proof-of-concept studyĀ ofĀ ADS-5102Ā (amantadineĀ HCl), showing that multiple sclerosis patients givenĀ the extended-release oral treatment improved their walking speed, will be presentedĀ at ACTRIMS 2017Ā this week. Findings in theĀ poster, ā€œA Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,ā€…

Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties

Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, inĀ multiple sclerosis (MS) patients with difficulties inĀ walking. The trial (NCT02471222),Ā aĀ double-blind, placebo-controlled and two-arm parallel groupĀ study,Ā evaluated ADS-5102 given once dailyĀ at 340 mg, at bedtime, for four…

Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl)

Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the companyā€™s product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…